Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Operating Income (2018 - 2025)

Historic Operating Income for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$7.4 million.

  • Inmune Bio's Operating Income rose 3950.02% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.4 million, marking a year-over-year decrease of 2365.75%. This contributed to the annual value of -$42.6 million for FY2024, which is 4335.43% down from last year.
  • Per Inmune Bio's latest filing, its Operating Income stood at -$7.4 million for Q3 2025, which was up 3950.02% from -$24.6 million recorded in Q2 2025.
  • Inmune Bio's Operating Income's 5-year high stood at -$4.5 million during Q1 2021, with a 5-year trough of -$24.6 million in Q2 2025.
  • Its 5-year average for Operating Income is -$8.9 million, with a median of -$8.4 million in 2023.
  • The largest annual percentage gain for Inmune Bio's Operating Income in the last 5 years was 3950.02% (2025), contrasted with its biggest fall of 14907.25% (2025).
  • Quarter analysis of 5 years shows Inmune Bio's Operating Income stood at -$9.0 million in 2021, then soared by 37.52% to -$5.6 million in 2022, then tumbled by 48.51% to -$8.4 million in 2023, then fell by 12.98% to -$9.5 million in 2024, then grew by 21.49% to -$7.4 million in 2025.
  • Its last three reported values are -$7.4 million in Q3 2025, -$24.6 million for Q2 2025, and -$9.9 million during Q1 2025.